Last updated: September 25, 2026
Advil PM is an over-the-counter combination of ibuprofen and diphenhydramine citrate marketed in the United States by Haleon. Its commercial position depends on brand recognition, retail distribution, consumer trust, and the convenience of combining nighttime pain relief with a sleep-aid ingredient. It does not have the exclusivity profile of a prescription drug because its active ingredients are available under FDA over-the-counter monograph pathways.
Haleon does not report Advil PM revenue separately. Public financial data therefore support analysis of the Advil franchise, Haleon’s pain-relief category, and the broader U.S. OTC analgesic and sleep-aid markets rather than a product-level income statement.
What is Advil PM and how does it work?
Advil PM contains two active ingredients:
| Ingredient |
Typical Advil PM amount per caplet |
Function |
| Ibuprofen |
200 mg |
Nonsteroidal anti-inflammatory drug for pain and fever |
| Diphenhydramine citrate |
38 mg, equivalent to 25 mg diphenhydramine |
Antihistamine used as a nighttime sleep aid |
The product is labeled for occasional sleeplessness associated with minor aches and pains. It is not labeled as a treatment for chronic insomnia, chronic pain, or long-term daily use. The product is generally marketed in caplet and liqui-gel formats, with package counts varying by retailer and channel.
The dual-action proposition is commercially straightforward: consumers receive analgesia from ibuprofen and sedation from diphenhydramine in a single product. That proposition differentiates Advil PM from standard ibuprofen products and creates direct competition with Tylenol PM and store-brand nighttime analgesics.
What is the FDA regulatory status of Advil PM?
Advil PM is an OTC drug product regulated primarily through FDA monograph requirements rather than through a modern prescription NDA exclusivity framework.
The applicable regulatory framework includes:
- FDA OTC analgesic and antipyretic requirements for ibuprofen.
- FDA OTC nighttime sleep-aid requirements for diphenhydramine.
- Labeling, dosage, warnings, and safety requirements under the Federal Food, Drug, and Cosmetic Act and Title 21 of the Code of Federal Regulations.
- Facility, manufacturing, quality, and post-market reporting obligations applicable to OTC drug manufacturers.
Ibuprofen is an established OTC active ingredient. Diphenhydramine is also an established OTC nighttime sleep-aid ingredient. The combination is therefore exposed to direct competition from other manufacturers that can formulate comparable products while complying with FDA monograph conditions.
What is the Orange Book status of Advil PM?
Advil PM is not generally treated as an Orange Book-protected prescription product. The FDA Orange Book focuses on approved drug applications, including NDAs and abbreviated new drug applications. OTC monograph products typically do not receive the same Orange Book listing and patent-certification structure as NDA products.
As a result:
- Advil PM does not have a conventional Orange Book patent estate comparable to a branded prescription medicine.
- Generic manufacturers generally do not need to file Paragraph IV certifications against an Advil PM NDA.
- Market entry is governed more by OTC monograph compliance, manufacturing capability, trademark law, retail access, and formulation execution than by patent-based Hatch-Waxman litigation.
What patents protect Advil PM?
The principal commercial protections for Advil PM are not expected to come from active-ingredient patents. Ibuprofen and diphenhydramine are long-established molecules with extensive generic availability.
Potential forms of protection include:
| Protection type |
Relevance to Advil PM |
| Active-ingredient patent |
No meaningful current protection for ibuprofen or diphenhydramine |
| Combination patent |
Limited commercial value unless a specific formulation or use claim survives validity and infringement challenges |
| Formulation patent |
Possible for release profile, liquid-gel delivery, excipients, or manufacturing process, but not a central disclosed barrier to ordinary store-brand products |
| Trademark |
Important protection for the Advil name, logo, packaging, and brand identity |
| Trade dress |
May protect distinctive packaging elements, subject to competition-law limits |
| Manufacturing know-how |
Can support product quality, consistency, and cost control |
| Retail contracts |
Can affect shelf placement and promotional visibility but are not exclusivity rights |
Haleon’s strongest defensible assets are likely brand equity, consumer awareness, distribution, and retailer relationships. Those assets are harder for private-label competitors to replicate than the underlying active ingredients.
When does Advil PM lose exclusivity?
Advil PM has no single prescription-style patent expiration date that determines generic entry. The product’s effective exclusivity has already been eroded by the availability of store-brand and generic ibuprofen-diphenhydramine products.
The relevant commercial timeline is:
| Period |
Market development |
| Historical period |
Ibuprofen and diphenhydramine became established OTC ingredients |
| Brand expansion period |
Advil developed line extensions, including nighttime combination products |
| Current market |
Private-label and generic alternatives compete on price and retailer placement |
| Ongoing |
Haleon relies on brand preference, innovation, packaging, and distribution rather than molecule exclusivity |
Generic entry is therefore not a future cliff event. It is an existing condition.
How strong is the Advil PM patent estate?
The patent estate appears commercially weak relative to prescription pharmaceuticals but adequate for a branded OTC product.
Strengths
- The Advil trademark has substantial consumer recognition.
- The product benefits from established OTC ingredients and a familiar dosing proposition.
- Brand-level protection can support premium pricing over private-label products.
- Packaging, product presentation, and formulation know-how may increase the cost of exact copying.
Weaknesses
- The active ingredients are widely available.
- Competitors can sell products with the same active ingredients under generic or private-label names.
- OTC products face rapid retailer substitution.
- Product-level revenue is not separately disclosed, limiting external assessment of profitability and growth.
- Safety warnings for NSAIDs and sedating antihistamines constrain broad or chronic-use positioning.
The commercial moat is therefore brand-led rather than patent-led.
Which companies compete with Advil PM?
Advil PM competes across branded, generic, private-label, and substitute categories.
| Competitor or category |
Active-ingredient strategy |
Competitive position |
| Tylenol PM |
Acetaminophen plus diphenhydramine |
Major branded alternative; appeals to consumers seeking non-NSAID pain relief |
| Motrin PM |
Ibuprofen plus diphenhydramine |
Direct ingredient-level competitor where marketed and available |
| Store-brand ibuprofen PM |
Ibuprofen plus diphenhydramine |
Low-price substitute with high retailer leverage |
| Store-brand acetaminophen PM |
Acetaminophen plus diphenhydramine |
Competes for the same nighttime pain-relief occasion |
| Standalone ibuprofen |
Ibuprofen only |
Competes when consumers do not need a sleep-aid ingredient |
| Standalone diphenhydramine products |
Diphenhydramine only |
Competes for sleep-aid demand |
| Melatonin and other sleep products |
Non-diphenhydramine sleep ingredients |
Expands substitution beyond analgesic products |
The closest direct competitor is a private-label ibuprofen/diphenhydramine product. Tylenol PM is a major branded competitor but differs in analgesic ingredient and safety profile.
How does Advil PM compare with Tylenol PM?
| Factor |
Advil PM |
Tylenol PM |
| Pain-relief ingredient |
Ibuprofen |
Acetaminophen |
| Sleep-aid ingredient |
Diphenhydramine |
Diphenhydramine |
| Anti-inflammatory effect |
Yes |
No |
| Key safety concern |
Gastrointestinal bleeding, kidney injury, cardiovascular risk, NSAID interactions |
Liver toxicity risk, especially with excessive dosing or alcohol use |
| Consumer positioning |
Pain with inflammation or body aches |
General nighttime pain relief |
| Patent barrier |
Minimal current molecule protection |
Minimal current molecule protection |
| Main commercial moat |
Advil brand and pain-relief credibility |
Tylenol brand and broad analgesic recognition |
The two products compete for the same consumer occasion but are not clinically interchangeable for every patient. Risk labeling and consumer familiarity influence brand selection.
What market dynamics affect Advil PM sales?
Advil PM sales are shaped by five main factors.
OTC pain-relief demand
Pain-relief products have relatively resilient demand because consumers purchase them for headaches, muscle pain, back pain, arthritis symptoms, colds, and minor injuries. Demand can rise during seasonal illness periods and periods of increased household health spending.
Sleep-aid demand
Sleep-related demand broadens the addressable market but also exposes Advil PM to competition from melatonin, doxylamine, diphenhydramine-only products, behavioral sleep products, and prescription medicines.
Private-label pricing
Retailers can use store-brand products to pressure branded OTC prices. Private-label products often use the same active ingredients and similar dosage forms at lower prices. Inflation can increase private-label switching, while promotional activity can temporarily restore branded volume.
Retail distribution
Mass merchants, drugstores, grocery chains, warehouse clubs, e-commerce platforms, and pharmacy channels all matter. Shelf placement, search ranking, promotional displays, package size, and retailer-specific pricing influence unit velocity.
Safety and label sensitivity
Ibuprofen and diphenhydramine carry meaningful warnings. Consumers with gastrointestinal bleeding risk, kidney disease, certain cardiovascular conditions, pregnancy-related restrictions, antihistamine sensitivity, or medication interactions may avoid the product. These restrictions limit the potential for chronic-use expansion.
What is the financial trajectory for Advil PM and Haleon’s Advil business?
Haleon does not disclose Advil PM net sales, gross margin, operating income, or standalone growth. The available financial proxy is Haleon’s consolidated performance and its broader pain-relief portfolio.
Haleon became an independent consumer-health company following its separation from GSK. Its portfolio includes Sensodyne, Centrum, Voltaren, Panadol, Advil, and other consumer brands. The company has emphasized brand investment, price realization, supply-chain productivity, and geographic expansion as growth drivers.
The likely financial pattern for Advil PM is:
- Stable or modest unit demand in a mature U.S. category.
- Revenue support from list-price increases and package-size management.
- Margin pressure from retailer negotiations, promotional spending, and input costs.
- Stronger resilience than discretionary consumer goods because analgesics are frequently purchased for immediate needs.
- Limited product-specific upside without reformulation, new packaging, channel expansion, or broader brand-line innovation.
Advil PM is more likely to contribute predictable cash flow than high-growth revenue. The franchise can produce attractive economics if Haleon maintains a price premium and controls advertising and trade-spend intensity. Private-label substitution is the central risk to unit volume and margin.
What generic entry risks exist for Advil PM?
Generic entry risk is already present rather than prospective. The key risk is continued private-label share capture.
High-probability risks
- Lower-priced ibuprofen/diphenhydramine products gaining shelf space.
- E-commerce search results prioritizing price.
- Retailer-owned brands receiving preferred placement.
- Consumers switching during inflationary periods.
- Similar packaging and dosage claims reducing perceived differentiation.
Lower-probability risks
- A new delivery format that improves convenience.
- A competitor using stronger retail promotion or larger package economics.
- Consumer migration from diphenhydramine toward melatonin or other sleep products.
- Negative publicity involving NSAID or antihistamine safety.
Because the product is OTC, a competitor does not need to wait for patent expiration to enter with a compliant equivalent. The key barrier is commercial execution.
What patent litigation or Paragraph IV activity affects Advil PM?
No major, product-defining Paragraph IV litigation is associated with Advil PM as a conventional NDA product. The product’s competitive environment is primarily commercial and regulatory.
Potential disputes would more likely involve:
- Trademark infringement.
- Trade-dress imitation.
- False or misleading advertising.
- Product-quality allegations.
- Manufacturing or supply agreements.
- Retail distribution or promotional practices.
The absence of a major Paragraph IV litigation pathway reduces litigation-driven launch uncertainty. It also means Haleon has fewer patent mechanisms for delaying competing products.
What manufacturing and intellectual-property barriers exist?
Manufacturing barriers are moderate. A compliant manufacturer must control:
- Ibuprofen and diphenhydramine identity and assay.
- Blend uniformity and dosage accuracy.
- Dissolution and stability.
- Gel-cap or caplet production, depending on dosage form.
- Packaging integrity.
- Label compliance and warning presentation.
- Contamination controls and batch-release testing.
These requirements impose operational costs but do not create a high barrier for experienced OTC manufacturers. Contract manufacturers and major private-label suppliers can generally support comparable products.
The more durable intellectual-property barriers involve the Advil trademark, packaging, brand assets, consumer trust, and distribution relationships.
Key Takeaways
- Advil PM combines 200 mg ibuprofen with diphenhydramine citrate equivalent to 25 mg diphenhydramine per typical caplet.
- Haleon owns and markets the Advil brand in the United States.
- Haleon does not publicly report Advil PM revenue separately.
- Advil PM is primarily an OTC monograph product, not a prescription-style Orange Book exclusivity asset.
- There is no meaningful current molecule-level patent barrier protecting ibuprofen or diphenhydramine.
- Generic and private-label competition already exists.
- The main commercial moat is the Advil brand, supported by distribution, packaging, consumer trust, and retail execution.
- Tylenol PM is the principal branded alternative, while store-brand ibuprofen PM products create the strongest direct price pressure.
- Product growth is likely to be mature and incremental, with pricing and mix contributing more than unit expansion.
- The main downside risks are private-label substitution, retailer bargaining power, safety-related demand limits, and competition from non-drug sleep products.
FAQs About Advil PM Market and Exclusivity
Does Advil PM have a patent expiration date?
No single patent expiration date controls Advil PM market entry. The active ingredients are long-established, and competing OTC products are already available.
Is Advil PM listed in the FDA Orange Book?
Advil PM is not generally treated as an Orange Book-listed prescription product because it is marketed through the OTC regulatory framework rather than a conventional NDA exclusivity structure.
Can a generic manufacturer sell an ibuprofen and diphenhydramine product?
Yes. A manufacturer can market a compliant OTC product using these established active ingredients, subject to FDA requirements for formulation, labeling, manufacturing, and quality.
Is Advil PM more profitable than regular Advil?
Public filings do not provide product-level profitability. Advil PM may support higher price realization than single-ingredient ibuprofen, but it also carries additional formulation, packaging, marketing, and safety-labeling considerations.
What is the biggest commercial threat to Advil PM?
The largest threat is private-label substitution. Retailers can offer comparable active ingredients at lower prices and use shelf placement, promotions, and e-commerce ranking to redirect consumers.
References
-
Haleon plc. (2024). Annual report and financial statements 2023. Haleon.
-
Haleon plc. (2024). Half-year report 2024. Haleon.
-
U.S. Food and Drug Administration. (2024). Drug facts label: Advil PM. FDA.
-
U.S. Food and Drug Administration. (2024). Over-the-counter monograph drugs. FDA.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
-
Electronic Code of Federal Regulations. (2024). 21 C.F.R. Part 338: External analgesic drug products for over-the-counter human use. U.S. Government Publishing Office.
-
Electronic Code of Federal Regulations. (2024). 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. U.S. Government Publishing Office.
